Generic iron injection put to the test in healthy volunteers

NCT ID NCT07606105

Recruiting now Knowledge-focused Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 1 trial is comparing a generic version of the iron injection ferric carboxymaltose to the brand-name drug Injectafer in 70 healthy adults. The goal is to see if the generic works the same way in the body and is safe. Participants receive a single dose of either drug and have their blood levels of iron measured over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ferric carboxymaltose (iron injection)
What this could lead to: If successful, this could show that the generic iron injection is equivalent to the brand-name drug, potentially offering a lower-cost treatment option for iron deficiency.
What could go wrong: This is an early-stage trial in healthy people, not patients. It only measures how the drug moves through the body, not whether it treats disease. The generic may still fail to show equivalence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT

Contacts and locations

Locations

Central Hospital Shandong Province
RECRUITING

Jinan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.